CL2023001793A1 - Anticuerpos anti-componente de complemento y métodos de uso - Google Patents
Anticuerpos anti-componente de complemento y métodos de usoInfo
- Publication number
- CL2023001793A1 CL2023001793A1 CL2023001793A CL2023001793A CL2023001793A1 CL 2023001793 A1 CL2023001793 A1 CL 2023001793A1 CL 2023001793 A CL2023001793 A CL 2023001793A CL 2023001793 A CL2023001793 A CL 2023001793A CL 2023001793 A1 CL2023001793 A1 CL 2023001793A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- methods
- complement component
- complement
- component antibodies
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000002391 anti-complement effect Effects 0.000 title abstract 2
- 108010008730 anticomplement Proteins 0.000 title abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000036962 time dependent Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Anticuerpos anti-componente de complemento tales como anticuerpos anti-C1s y anticuerpos anti-C1r, y métodos para usar los mismos. La invención también proporciona formulaciones farmacéuticas que comprenden los anticuerpos y métodos para tratar a un individuo que tenga una enfermedad o trastorno mediado por el complemento que comprenden la administración del anticuerpo al individuo. Se evalúan la especificidad de unión y la función de desplazamiento de C1q de los anticuerpos anti-C1s y anticuerpos anti-C1r. La función de neutralización del complemento dependiente del tiempo y la unión a las proteínas C1s o C1r nativas y truncadas también se muestran para los anticuerpos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018077527 | 2018-04-13 | ||
| JP2018188770 | 2018-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001793A1 true CL2023001793A1 (es) | 2023-12-15 |
Family
ID=68164028
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002610A CL2020002610A1 (es) | 2018-04-13 | 2020-10-09 | Anticuerpos anti-componente de complemento y métodos de uso |
| CL2023001793A CL2023001793A1 (es) | 2018-04-13 | 2023-06-16 | Anticuerpos anti-componente de complemento y métodos de uso |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002610A CL2020002610A1 (es) | 2018-04-13 | 2020-10-09 | Anticuerpos anti-componente de complemento y métodos de uso |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210198347A1 (es) |
| EP (1) | EP3774892A4 (es) |
| JP (2) | JP7333789B2 (es) |
| KR (1) | KR20200143459A (es) |
| CN (1) | CN112313249A (es) |
| AU (1) | AU2019250403A1 (es) |
| BR (1) | BR112020018357A2 (es) |
| CA (1) | CA3094312A1 (es) |
| CL (2) | CL2020002610A1 (es) |
| CR (1) | CR20200542A (es) |
| IL (1) | IL277827A (es) |
| MA (1) | MA52248A (es) |
| MX (1) | MX2020010528A (es) |
| PE (1) | PE20201447A1 (es) |
| SG (1) | SG11202010125VA (es) |
| WO (1) | WO2019198807A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| EP3783017A1 (en) | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| AU2020275348A1 (en) * | 2019-05-15 | 2021-12-09 | Chugai Seiyaku Kabushiki Kaisha | An antigen-binding molecule, a pharmaceutical composition, and a method |
| JP2021063075A (ja) * | 2019-10-16 | 2021-04-22 | 中外製薬株式会社 | 抗体、薬学的組成物、および方法 |
| WO2022031978A1 (en) * | 2020-08-06 | 2022-02-10 | Bioverativ Usa Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| WO2022103871A1 (en) * | 2020-11-10 | 2022-05-19 | Wyomingv Immune, Inc. | Therapeutic compositions for the treatment of covid-19 |
| AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
| EP4337332A2 (en) | 2021-07-13 | 2024-03-20 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
| CN117327732A (zh) * | 2022-12-31 | 2024-01-02 | 义翘神州(泰州)科技有限公司 | 充分自裂解重组C1s蛋白的表达质粒组合、表达宿主细胞及表达方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
| HUP0900319A2 (en) * | 2009-05-25 | 2011-01-28 | Eotvos Lorand Tudomanyegyetem | New peptides, method of producing therof and use thereof |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| IN2015KN00015A (es) * | 2012-06-18 | 2015-07-31 | Omeros Corp | |
| US20160053023A1 (en) * | 2013-04-09 | 2016-02-25 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| WO2014186599A2 (en) * | 2013-05-15 | 2014-11-20 | Annexon, Inc. | Anti-complement factor c1s antibodies and uses thereof |
| AU2015343029B2 (en) * | 2014-11-05 | 2021-07-29 | Annexon, Inc. | Humanized anti-complement factor C1q antibodies and uses thereof |
| HRP20230093T1 (hr) * | 2015-04-06 | 2023-03-31 | Bioverativ Usa Inc. | Humanizirana anti-c1s protutijela i postupci njihove primjene |
| JP6976943B2 (ja) * | 2015-11-24 | 2021-12-08 | アネクソン，インコーポレーテッド | 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用 |
-
2019
- 2019-04-12 BR BR112020018357-1A patent/BR112020018357A2/pt unknown
- 2019-04-12 KR KR1020207032744A patent/KR20200143459A/ko unknown
- 2019-04-12 JP JP2020555924A patent/JP7333789B2/ja active Active
- 2019-04-12 PE PE2020001585A patent/PE20201447A1/es unknown
- 2019-04-12 WO PCT/JP2019/015919 patent/WO2019198807A1/en active Application Filing
- 2019-04-12 EP EP19784866.6A patent/EP3774892A4/en active Pending
- 2019-04-12 CR CR20200542A patent/CR20200542A/es unknown
- 2019-04-12 MX MX2020010528A patent/MX2020010528A/es unknown
- 2019-04-12 CN CN201980038684.5A patent/CN112313249A/zh active Pending
- 2019-04-12 MA MA052248A patent/MA52248A/fr unknown
- 2019-04-12 US US17/046,395 patent/US20210198347A1/en not_active Abandoned
- 2019-04-12 AU AU2019250403A patent/AU2019250403A1/en active Pending
- 2019-04-12 CA CA3094312A patent/CA3094312A1/en active Pending
- 2019-04-12 SG SG11202010125VA patent/SG11202010125VA/en unknown
-
2020
- 2020-10-06 IL IL277827A patent/IL277827A/en unknown
- 2020-10-09 CL CL2020002610A patent/CL2020002610A1/es unknown
-
2023
- 2023-06-16 CL CL2023001793A patent/CL2023001793A1/es unknown
- 2023-08-15 JP JP2023132187A patent/JP2023154049A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3094312A1 (en) | 2019-10-17 |
| CR20200542A (es) | 2021-01-18 |
| JP2023154049A (ja) | 2023-10-18 |
| PE20201447A1 (es) | 2020-12-10 |
| WO2019198807A1 (en) | 2019-10-17 |
| SG11202010125VA (en) | 2020-11-27 |
| MX2020010528A (es) | 2020-11-06 |
| EP3774892A1 (en) | 2021-02-17 |
| AU2019250403A1 (en) | 2020-11-19 |
| KR20200143459A (ko) | 2020-12-23 |
| JP7333789B2 (ja) | 2023-08-25 |
| CL2020002610A1 (es) | 2021-02-12 |
| BR112020018357A2 (pt) | 2020-12-29 |
| EP3774892A4 (en) | 2022-02-16 |
| IL277827A (en) | 2020-11-30 |
| MA52248A (fr) | 2021-02-17 |
| CN112313249A (zh) | 2021-02-02 |
| JP2021521206A (ja) | 2021-08-26 |
| US20210198347A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001793A1 (es) | Anticuerpos anti-componente de complemento y métodos de uso | |
| CL2023003010A1 (es) | Novedosas proteínas de la cápside del virus adenoasociado | |
| PE20220256A1 (es) | Sistemas de casx artificiales | |
| CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
| PE20210685A1 (es) | Anticuerpos que se dirigen al gp120 de vih y metodos de uso | |
| CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
| PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
| CO2018004743A2 (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| AR115097A1 (es) | Vectores virales adenoasociados dirigidos al hígado | |
| CL2019001129A1 (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y. | |
| CO2019002482A2 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| CO2021008665A2 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| CL2021000849A1 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999) | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| CL2023000524A1 (es) | Compuestos fosfolípidos y usos de los mismos | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| CL2019001354A1 (es) | Administración intratecal de virus recombinante adeno–asociado que codifica la proteína 2 que une metilo–cpg. | |
| CO2021014748A2 (es) | Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo | |
| CO2020009043A2 (es) | Anticuerpos humanos contra hemaglutinina de influenza | |
| ECSP16091728A (es) | Droga antiretroviral dirigida a un retrovirus endógeno humano | |
| CO2020013557A2 (es) | Variantes de lfa3 y composiciones y usos de las mismas | |
| AR119104A1 (es) | Sistemas de casx artificiales | |
| AR116106A1 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso |